title: Solanezumab and the amyloid hypothesis for Alzheimer's disease.
authors.affiliation: Centre for Education and Research on Ageing, Concord Hospital and University of Sydney, Sydney, Australia david.lecouteur@sydney.edu.au.
authors.forename: David G
authors.initials: DG
authors.lastname: Le Couteur
authors.affiliation: Cambridge Institute of Public Health, Cambridge, UK.
authors.forename: Sally
authors.initials: S
authors.lastname: Hunter
authors.affiliation: Cambridge Institute of Public Health, Cambridge, UK.
authors.forename: Carol
authors.initials: C
authors.lastname: Brayne
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D058225:Plaque, Amyloid / Q000188:drug therapy* / Q000378:metabolism; D017211:Treatment Failure
chemical_list: D016229:Amyloid beta-Peptides; D061067:Antibodies, Monoclonal, Humanized; C550616:solanezumab